Last reviewed · How we verify
NCT05520892
Two Regimens of IVIG in the Treatment of Newly Diagnosed ITP in Children
Phase 4 trial testing intravenous immunoglobulin in Newly Diagnosed Immune Thrombocytopenia in Children, First Line Treatment in 580 participants. Currently enrolling.
31 August 2025
Quick facts
| Lead sponsor | Fujian Medical University Union Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 580 |
| Start date | 6 October 2022 |
| Primary completion | 31 August 2025 |
| Estimated completion | 31 August 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- intravenous immunoglobulin — full drug profile →
Conditions studied
- Newly Diagnosed Immune Thrombocytopenia in Children, First Line Treatment — all drugs for Newly Diagnosed Immune Thrombocytopenia in Children, First Line Treatment →
Sponsor
Fujian Medical University Union Hospital
Who can join
Adults 29 Days to 14, any sex, with Newly Diagnosed Immune Thrombocytopenia in Children, First Line Treatment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia, and to reduce related adverse reactions and economic burdens on the premise of ensuring the remission rate
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05520892
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of intravenous immunoglobulin
Trials testing the same drug.
- NCT05114941 — Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome · NA · not yet recruiting
- NCT05634824 — IVIg Plus Low Dose rhTPO for ITP in Pregnancy · Phase 2 · unknown
- NCT05604859 — Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS) · Phase 4 · unknown
- NCT05134792 — Effect of Pre-emptive Intravenous Immunoglobulin (IVIG) on the Incidence of Septic Episodes in Pediatric Burn Patients · Phase 2, PHASE3 · completed
- NCT03130517 — Efficacy of Intravenous Immunoglobulin in Management of Rh and ABO Incompatibility Disease · EARLY_PHASE1 · unknown
Other Fujian Medical University Union Hospital trials
Trials by the same sponsor.
- NCT07406815 — The Value of Near-Infrared Fluorescence Imaging in the Protection of the Recurrent Laryngeal Nerve During Minimally Inva · Phase 3 · not yet recruiting
- NCT07444983 — Rezvilutamide for High-Risk Prostate Cancer After Surgery · NA · not yet recruiting
- NCT07493070 — Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver Ca · NA · active not recruiting
- NCT07389889 — Percutaneous Robotic Navigation Microwave Ablation Versus CT-guided Microwave Ablation in the Treatment of Pulmonary Nod · NA · not yet recruiting
- NCT07303231 — The Value of Indocyanine Green-guided Near-infrared Fluorescence Technology in Tracing Sentinel Lymph Nodes During Esoph · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05520892 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Medical University Union Hospital
- Last refreshed: 16 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05520892.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing